AFFILIATIONS
1 Columbia Stem Cell Initiative, New York, New York, United States, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, United States
2 Columbia Stem Cell Initiative, New York, New York, United States, Division of Hematology/Oncology, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
3 Columbia Stem Cell Initiative, New York, New York, United States, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
4 Columbia Stem Cell Initiative, New York, New York, United States, Division of Hematology/Oncology, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
5 Columbia Stem Cell Initiative, New York, New York, United States, Division of Hematology/Oncology, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
6 Columbia Stem Cell Initiative, New York, New York, United States, Division of Hematology/Oncology, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
7 Columbia Stem Cell Initiative, New York, New York, United States, Division of Hematology/Oncology, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
8 Columbia Stem Cell Initiative, New York, New York, United States, Division of Hematology/Oncology, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
9 Columbia Stem Cell Initiative, New York, New York, United States, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, United States, Division of Hematology/Oncology, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
ABSTRACT
Background: Megakaryopoiesis is tightly linked to hematopoietic stem cell (HSC) function and is frequently disrupted in myelodysplastic syndromes (MDS). We previously demonstrated that loss of STAG2, a core component of the cohesin complex and a recurrent early MDS mutation, skews megakaryocyte-erythroid progenitors toward megakaryopoiesis and away from erythropoiesis while promoting megakaryocyte (MK) dysplasia. Despite these observations, Stag2-deficient mice develop persistent thrombocytopenia, creating a paradox in which increased megakaryopoiesis fails to generate adequate platelet production. We hypothesized that STAG2 loss promotes MK lineage commitment while impairing terminal MK maturation.
Methods: Stag2-deficient and wild-type mice were analyzed using flow cytometry, platelet activation and aggregation assays, and megakaryocyte ploidy assessment. Transcriptional analyses were performed to evaluate direct megakaryopoiesis programs and HSC lineage priming. To define the molecular basis of altered megakaryopoiesis, RNA-seq and ATAC-seq were performed on purified megakaryocytes. Complementary FLK2-switch lineage-tracing studies were initiated to assess direct HSC-to-megakaryocyte differentiation.
Results: Consistent with prior observations, Stag2-deficient mice demonstrated persistent thrombocytopenia despite increased MK output and increased MK progenitor frequency. Transcriptional analyses revealed increased expression of direct megakaryopoiesis programs and persistent CD41 expression within HSCs, suggesting that Stag2-deficient HSCs are primed toward MK fate and preferentially engage direct HSC-to-MK differentiation pathways.
Platelet activation and aggregation did not differ between Stag2-deficient and wild-type mice, indicating that thrombocytopenia results from impaired platelet production rather than intrinsic platelet dysfunction. Examination of megakaryocyte maturation demonstrated a marked shift toward low-ploidy megakaryocytes with reciprocal depletion of highly polyploid populations, consistent with impaired endomitosis and defective terminal maturation.
RNA-seq and ATAC-seq analyses were performed to define the transcriptional and chromatin-accessibility programs underlying these maturation defects. Based on these observations, we hypothesize that STAG2 loss uncouples chromatin accessibility from FLI1- and GATA1-dependent transcriptional regulation, enhancing MK lineage priming while disrupting maturation-associated regulatory programs at key loci including Itga2b and Gp1ba. In parallel, we are employing the FLK2-switch lineage-tracing model to determine whether STAG2 loss preferentially redirects hematopoiesis toward direct HSC-to-MK differentiation.
Conclusions: STAG2 loss uncouples megakaryocyte lineage commitment from terminal maturation. Increased megakaryocyte-biased output and direct megakaryopoiesis are accompanied by defective endomitosis and impaired maturation, providing a mechanistic explanation for persistent thrombocytopenia despite expansion of the megakaryocytic compartment. These findings identify a previously unrecognized role for STAG2-cohesin in coordinating megakaryocyte fate specification and maturation.